Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711970 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
A Phase 1 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01711970 is a Phase 1 study that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 38 participants.
The verdict
NCT01711970, a Phase 1 study, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum resistant ovarian cancer.
Interventions
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-11 |
| Est. Completion | 2017-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711970
The ClinicalTrials.gov registry entry for NCT01711970 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.
NCT01711970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711970 about?
NCT01711970 is a clinical study titled "A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer". This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum resistant ovarian cancer.
What is the current status of trial NCT01711970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2012-11. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT01711970?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01711970?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.